Tropical Diseases: An unsolved challenge

International Journal of PharmTech Research

Volumn 2, Issue 3, 2010, Pages 1691-1698

  Somani, Rakesh R ^a   Gavarkar, Pratibha S ^a   Shirodkar, Prabhakar Y ^a   Bhanushali, Umesh V ^a   Kadam, Vilasrao J ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Drug molecules; Drug targets; Malaria; Pathogens; Tropical diseases; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; AMODIAQUINE PLUS ARTESUNATE; AMPHOTERICIN B; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; CAPREOMYCIN; CHLOROQUINE; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DAPSONE; DENGUE VACCINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MEFLOQUINE; MEGLUMINE; OFLOXACIN; PRIMAQUINE; PROGUANIL; PYRAZINAMIDE; QUININE; QUINOLONE DERIVATIVE; RIFAMPICIN; SITAMAQUINE; SPARFLOXACIN; STIBOGLUCONATE SODIUM; UNINDEXED DRUG;

ARTICLE; DENGUE; DISEASE CONTROL; HUMAN; LEISHMANIASIS; LEPROSY; MALARIA; NONHUMAN; PUBLIC HEALTH; TROPICAL DISEASE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 77957598034     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Diamond J, Guns, Germs, and Steel: The Fates of Human Societies, W.W. Norton & Company, 1997.
2. "Disease portfolio" Special Programme for Research and Training in Tropical Diseases. http://www.who.int/tdr/diseases/default.htm Retrieved on 2008-01-21.
3. Hotez P. J, Control of Neglected Tropical Diseases, The New England Journal of Medicine, 2007, 357 (10), 1018-1027.
4. Snow R. W, Guerra C. A., Noor A. M, Myint H. Y, Hay S, The global distribution of clinical episodes of Plasmodium falciparum malaria, Nature, 2005, 434 (7030), 214-217.
5. Singh B, Kim Sung L, Matusop A et al., The global distribution of clinical episodes of Plasmodium falciparum malaria, Lancet, 2004, 363 (9414), 1017-1024.
6. Emmanuel C. Ibezim and Uche Odo, Current trends in malarial chemotherapy, African Journal of Biotechnology, 2008, 7 (4), 349-356.
7. Beare N. A., Taylor T.E., Harding S. P, Lewallen S., Molyneux M. E., Malarial retinopathy: a newly established diagnostic sign in severe malaria, Am. J. Trop. Med. Hyg., 2006, 75 (5), 790-797.
8. Minton June, Infectious Diseases-Tropical Diseases Seen in UK Hospitals, Hospital Pharmacist, 2004, 11, 271-278.
9. Nosten F. et al. "Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study," The Lancet, 2000, 356, 297-302.
10. Padmanaban Govindarajan, V. Arun Nagaraj and Pundi N. Rangarajan, Drugs and drug targets against malaria, Current Science, 2007, 92 (11), 1545-1555.
11. Nussenzweig R., Vanderberg J., Most H., Orton C.,"Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei", Nature, 1967, 216 (5111), 160-162.
12. World Health Organization, Global tuberculosis control report Fact sheet N°104, 2007.
13. Kumar Vinay, Abbas Abul K., Fausto Nelson, Richard N. Mitchell, Robbins Basic Pathology, 8th ed., Saunders Elsevier, 2007, 516-522.
14. Freidan T.R., Sterling T. R., Munsiff S. S., Watt C. J., Dye C., Tuberculosis (Seminar), The Lancet, 2003, 362(9387), 887-889.
15. Sutherland I., Recent studies in the epidemiology of tuberculosis based on the risk of being infected with tubercle bacilli, Adv Tuberc Res, 1976, 19, 1-63.
16. Chopra Puneet, Meena L. S. and Singh Yogendra, New drug targets for Mycobacterium tuberculosis, Indian J. Med. Res., 2003, 117, 1-9.
17. Johnson Rabia, Stricher Elizabeth M., Gail E. Louw, Robbin M. Warren, Paul D. Van Helden and Thomas C. Victor, Drug resistance in Mycobacterium tuberculosis, Current Issues Mol. Bio., 8, 97-112.
18. McKinney J. D., Honer Zu Bentrup K, Munoz - Elias E. J., Miczak A., Chen B., Chan W. T. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase, Nature, 2000, 406, 735-8.
19. Glickman M. S., Jacobs W. B., Jr. Microbial pathogenesis of Mycobacterium tuberculosis dawn of a discipline, Cell, 2001, 104, 477-85.
20. Berthet F. X., Lagranderie M., Gounon P., Laurent-Winter C., Ensergueix D., Chavarot P. et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene, Science, 1998, 282, 759-762.
21. Doukhan L., Predich M., Nair G., Dussurget O., Mandic- Mulec I., Cole S. T. et al. Genomic organization of themycobacterial sigma gene cluster, Gene, 1995, 165, 67-70.
22. Buchmeier N., Blanc-Potard A., Ehrt S., Piddington D., Riley L., Groisman E. A., A parallel intraphagosomal survival strategy shared by Mycobacterium tuberculosis and Salmonella enterica, Mol Microbiol, 2000, 35,1375-1382.
23. Rui-feng Qi, Ling Zhang and Cheng-wu Chi, Biological characteristics of dengue virus and potential targets for drug design, Acta Biochem. Biophys. Sin., 2008, 40, 91-101.
24. Tewari S. C. et al. Dengue vector prevalence and virus infection in a rural area in South India, Tropical Medicine and International Health; 2004, April, 9(4), 499-507.
25. www.who.int/emc/disease/eboa/Denguepublication/index.htm.
26. World Health Organization. Prevention and control of dengue and dengue haemorrhagic fever: Comprehensive guidelines. WHO regional publication, SEARO, 1999, 3-53.
27. Vu S. N., Nguyen T. Y., Kay B. H., Marten G. G., Reid J. W., Am. J. Trop. Med. Hyg., 1998, 59(4), 657-660.
28. Zheng Yin, Patel Sejal J., Wei-Ling Wang, Gang Wang, Wai-Ling Chan, Ranga Rao K.R., Jenefer Alam, Duraiswamy A. Jeyaraj, Xinyi Ngew, Patel Viral, Beer David, Siew Pheng Lim, Vasudevan Subhash G., Keller Thomas H., Peptide inhibitors of dengue virus NS3 protease, Part 1: Warhead, Bioorganic & Medicinal Chemistry Letters, 2006, 16 (1), 36-39.
29. Zhang Y., Corver J., Chipman P. R, Zhang W, Pletnev S. V., Sedlak D., Baker T. S. et al. Structures of immature flavivirus particles. EMBO J 2003, 22, 2604-2613.
30. Cahour A., Falgout B., Lai C. J., Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease, J Virol,1992, 66, 1535-1542.
31. Sasaki S., Takeshita F., Okuda K., Ishii N., Mycobacterium leprae and leprosy: a compendium, Microbiol. Immunol., 2001, 45, 729-736.
32. World Health Organization, Leprosy - Global situation. Weekly epidemiological record, 2000, 75, 225-232.
33. Lockwood D. N., Kumar B., Treatment of leprosy, BMJ, 2004 Jun 19, 328(7454), 1447-1448.
34. K. D. Tripathi, Essentials of Medical Pharmacology, 5th ed., 2003, 709-711.
35. WHO model prescribing information - drug used in leprosy, WHO/DMP/DSI/98.1, WHO, Geneva (1998).
36. World Health Organisation (WHO) - Leprosy: the disease
37. Haimanot R. T., Melaku Z., Leprosy, Curr Opin Neurol. 2000 Jun, 13(3), 317-322.
38. World Health Organization. The final push strategy to eliminate leprosy as a public health problem; 2003.
39. TDR; The Special Programme for Research and Training in Tropical Diseases, 2002. Strategic direction for research - Leprosy.
40. Singh Neeloo, Drug resistance mechanisms in clinical isolates of Leishmania donovani, Indian J Med Res, March 2006, 123, 411-422.
41. Soto J., Toledo J. T., Oral miltefosine to treat new world cutaneous leishmaniasis, Lancet Infect Dis, 2007, 7(1), 7.
42. Arevalo J., Ramirez L., Adaui V. et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis, J. Infect. Dis., June 2007, 195 (12), 1846-51.
43. Sundar S., Chakravarty J., Rai V. K. et al. Amphotericin B treatment for Indian visceral leishmaniasis response to 15 daily versus alternateday infusions, Clin. Infect. Dis., September 2007, 45 (5), 556-61.
44. Simon L. Croft and Graham H. Coombs, Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs, Trends in Parasitology, November 2003, 19(11), 502-508.